We reviewed trials that tested the efficacy of antihypertensive drugs in reducing arterial stiffness and wave reflections as assessed by pulse wave velocity and augmentation index, respectively. Regardless of cross-over or parallel-group comparison design, placebo-controlled trials demonstrated that antihypertensive drugs were effective in reducing pulse wave velocity. In actively-controlled parallel-group comparison studies, this effect on arterial stiffness was more evident for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers than other classes of antihypertensive drugs, particularly when brachial-ankle pulse wave velocity was measured. Regardless of cross-over or parallel-group comparison or placebo- or actively-controlled design, the reviewed trials showed that β-blockers were inferior to all the other classes of antihypertensive drugs in reducing augmentation index. However, these studies had a small sample size and a short follow-up time and did not link the changes in measurements of arterial function with cardiovascular events. Whether the superiority or inferiority is clinically relevant for cardiovascular protection and prevention remains to be investigated.

Keywords:
Antihypertensive drugs, Arterial stiffness, Wave reflections, Randomized controlled trial
1.
Vlachopoulos C, Aznaouridis K, Stefanadis C: Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-1327.
2.
Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C: Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31:1865-1871.
3.
Pannier BM, Guerin AP, Marchais SJ, London GM: Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001;28:1074-1077.
4.
Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ: Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 2002;103:493-499.
5.
Morgan T, Lauri J, Bertram D, Anderson A: Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-123.
6.
Hirata K, Vlachopoulos C, Adji A, O'Rourke MF: Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-556.
7.
Turner CL, Wilkinson IB, Kirkpatrick PJ: Use of antihypertension agents for the suppression of arterial pulse pressure waveforms in patients with intracranial aneurysms. J Neurosurg 2006;104:531-536.
8.
Asmar R, Gosse P, Topouchian J, N'Tela G, Dudley A, Shepherd GL: Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst 2002;3:176-180.
9.
Rajagopalan S, Kariisa M, Dellegrottaglie S, Bard RL, Kehrer C, Matlow S, Daley W, Pitt B, Brook R: Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial. J Clin Hypertens (Greenwich) 2006;8:783-790.
10.
Kaufman R, Nunes I, Bolognese JA, Miller DL, Salotti D, McCarthy JM, Smith WB, Herman GA, Feig PU: Single-dose effects of isosorbidemononitrate alone or in combination with losartan on central blood pressure. J Am Soc Hypertens 2010;4:311-318.
11.
Asmar RG, Kerihuel JC, Girerd XJ, Safar ME: Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991;68:61-64.
12.
Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB: A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008;26:351-356.
13.
Davies J, Gavin A, Band M, Morris A, Struthers A: Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. Br J Clin Pharmacol 2005;59:520-523.
14.
Kahonen M, Ylitalo R, Koobi T, Turjanmaa V, Ylitalo P: Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers. Int J Clin Pharmacol Ther 1998;36:483-489.
15.
Dart AM, Reid CM, McGrath B: Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension. Am J Hypertens 2001;14:804-810.
16.
Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, Yoshizawa M, Furukawa T, Takenaka T, Saruta T: Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 2005;45:866-874.
17.
Yu WC, Lin YP, Lin IF, Chuang SY, Chen CH: Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis 2006;47:478-484.
18.
Tsang TS, Barnes ME, Abhayaratna WP, Cha SS, Gersh BJ, Langins AP, Green TD, Bailey KR, Miyasaka Y, Seward JB: Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol 2006;97:916-920.
19.
Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, Dart AM, Kingwell BA: Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 2007;298:1539-1547.
20.
Rahman S, Ismail AA, Ismail SB, Naing NN, Abdul RA: Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Eur J Clin Pharmacol 2007;63:733-741.
21.
Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA: Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007;49:1271-1277.
22.
Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA: Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens 2008;26:1037-1042.
23.
Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE: AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 2002;20:2423-2428.
24.
Mitsuhashi H, Tamura K, Yamauchi J, Ozawa M, Yanagi M, Dejima T, Wakui H, Masuda S, Azuma K, Kanaoka T, Ohsawa M, Maeda A, Tsurumi-Ikeya Y, Okano Y, Ishigami T, Toya Y, Tokita Y, Ohnishi T, Umemura S: Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009;207:186-190.
25.
Kahonen M, Ylitalo R, Koobi T, Turjanmaa V, Ylitalo P: Influences of nonselective, beta(1)-selective and vasodilatory beta(1)-selective beta-blockers on arterial pulse wave velocity in normotensive subjects. Gen Pharmacol 2000;35:219-224.
26.
Ylitalo R, Kahonen M, Nieminen T, Koobi T, Ylitalo P, Turjanmaa V: Effects of a mononitrate, a beta1-blocker and a dihydropyridine calcium channel blocker on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study in normotensive volunteers. Arzneimittelforschung 2005;55:160-166.
27.
London GM, Marchais SJ, Guerin AP, Metivier F, Safar ME, Fabiani F, Froment L: Salt and water retention and calcium blockade in uremia. Circulation 1990;82:105-113.
28.
Asmar R, Benetos A, Brahimi M, Chaouche K, Safar M: Arterial and antihypertensive effects of nitrendipine: a double-blind comparison versus placebo. J Cardiovasc Pharmacol 1992;20:858-863.
29.
Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN: Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009;54:505-512.
30.
Mahmud A, Feely J: Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002;15:321-325.
31.
Ali K, Rajkumar C, Fantin F, Schiff R, Bulpitt CJ: Irbesartan improves arterial compliance more than lisinopril. Vasc Health Risk Manag 2009;5:587-592.
32.
Chen CH, Ting CT, Lin SJ, Hsu TL, Yin FC, Siu CO, Chou P, Wang SP, Chang MS: Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995;25:1034-1041.
33.
Neal DA, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJ: Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 2004;77:748-750.
34.
Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT: Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006;24:1397-1403.
35.
Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB: Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-219.
36.
Izzo JJ, Rajpal M, Karan S, Srikakarlapudi S, Osmond PJ: Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress. J Am Soc Hypertens 2012;6:117-123.
37.
Asmar RG, Benetos A, Chaouche-Teyara K, Raveau-Landon CM, Safar ME: Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. Am J Cardiol 1993;72:794-798.
38.
Ferguson JM, Minas J, Siapantas S, Komesaroff PA, Sudhir K: Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. J Cardiovasc Pharmacol 2008;51:590-595.
39.
Rajzer M, Klocek M, Kawecka-Jaszcz K: Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003;16:439-444.
40.
Takami T, Shigemasa M: Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003;26:609-614.
41.
Anan F, Takahashi N, Ooie T, Yufu K, Hara M, Nakagawa M, Yonemochi H, Saikawa T, Yoshimatsu H: Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 2005;61:353-359.
42.
Rehman A, Ismail SB, Naing L, Roshan TM, Rahman AR: Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malay hypertensive subjects with a known genetic profile. Am J Hypertens 2007;20:184-189.
43.
Li Y, Ma SM, Du M, Chu WW, Cheng XM: Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 2009;37:908-912.
44.
Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB: Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009;54:409-413.
45.
London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994;90:2786-2796.
46.
Morimoto S, Maki K, Aota Y, Sakuma T, Iwasaka T: Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function. Hypertens Res 2008;31:1603-1610.
47.
Breithaupt-Grogler K, Leschinger M, Belz GG, Butzer R, Erb K, de May C, Sinn W: Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. Cardiovasc Drugs Ther 1996;10:49-57.
48.
Jiang XJ, Li QY, Zhang YQ, Liu GZ, Liu LS: The comparison of the effect of enalapril and indapamide on the peripheral blood pressure and central blood pressure through pulse wave analysis (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 2005;33:885-888.
49.
Kostka-Jeziorny K, Uruski P, Tykarski A: Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press 2011;20:104-110.
50.
Boutouyrie P, Achouba A, Trunet P, Laurent S: Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010;55:1314-1322.
51.
Vitale C, Marazzi G, Iellamo F, Spoletini I, Dall'Armi V, Fini M, Volterrani M: Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol 2012;155:279-284.
52.
Munakata M, Nagasaki A, Nunokawa T, Sakuma T, Kato H, Yoshinaga K, Toyota T: Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004;17:1050-1055.
53.
Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M: Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006;20:787-794.
54.
Morimoto S, Yano Y, Maki K, Sawada K: Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006;29:567-572.
55.
Kosch M, Levers A, Lang D, Bartels V, Rahn KH, Pavenstadt H, Hausberg M: A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant 2008;23:2280-2285.
56.
Ishii H, Tsukada T, Yoshida M: Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients. Intern Med 2008;47:2013-2018.
57.
Schneider MP, Delles C, Klingbeil AU, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE: Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. J Renin Angiotensin Aldosterone Syst 2008;9:49-56.
58.
Tomiyama H, Yoshida M, Yamada J, Matsumoto C, Odaira M, Shiina K, Yamashina A: Arterial-cardiac destiffening following long-term antihypertensive treatment. Am J Hypertens 2011;24:1080-1086.
59.
Merli I, Simon A, Del PM, Brautigam M, Welzel D, Levenson J: Intrinsic effect of antihypertensive treatment with isradipine and metoprololon large artery geometric and elastic properties. Clin Pharmacol Ther 1993;54:76-83.
60.
White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-1026.
61.
Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225.
62.
Kaneshiro Y, Ichihara A, Sakoda M, Kurauchi-Mito A, Kinouchi K, Itoh H: Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 2009;32:51-58.
63.
Doi M, Miyoshi T, Hirohata S, Kamikawa S, Usui S, Kaji Y, Sakane K, Ogawa H, Ninomiya Y, Kusachi S: Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients. Am J Med Sci 2010;339:433-439.
64.
Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Shimada K, Kario K: Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study. Atherosclerosis 2011;215:184-188.
65.
Asmar RG, London GM, O'Rourke ME, Safar ME: Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001;38:922-926.
66.
Ding FH, Li Y, Li LH, Wang JG: Impact of heart rate on central hemodynamics and stroke: a meta-analysis of β-blocker trials. Am J Hypertens 2013;26:118-125.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.